Literature DB >> 33508243

Trifluridine/tipiracil plus ramucirumab in gastric cancer.

Mojun Zhu1, Mohamad Bassam Sonbol2, Harry H Yoon3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33508243      PMCID： PMC8447873          DOI： 10.1016/S2468-1253(21)00013-3

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


× No keyword cloud information.
  6 in total

1.  Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.

Authors:  Kohei Shitara; Kei Muro; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Yoshito Komatsu; Tomohiro Nishina; Kensei Yamaguchi; Yoshihiko Segawa; Yasushi Omuro; Takao Tamura; Toshihiko Doi; Seigo Yukisawa; Hirofumi Yasui; Fumio Nagashima; Masahiro Gotoh; Taito Esaki; Michael Emig; Kumari Chandrawansa; Astra M Liepa; Hansjochen Wilke; Yukako Ichimiya; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2015-10-28       Impact factor: 7.370

2.  Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.

Authors:  Akihito Kawazoe; Takayuki Ando; Hisashi Hosaka; Junya Fujita; Keisuke Koeda; Kazuhiro Nishikawa; Kenji Amagai; Kazumasa Fujitani; Kazuhiro Ogata; Keita Watanabe; Yuji Yamamoto; Kohei Shitara
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-01-26

3.  Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment.

Authors:  Yasuko Tada; Yosuke Togashi; Daisuke Kotani; Takeshi Kuwata; Eichi Sato; Akihito Kawazoe; Toshihiko Doi; Hisashi Wada; Hiroyoshi Nishikawa; Kohei Shitara
Journal:  J Immunother Cancer       Date:  2018-10-11       Impact factor: 13.751

4.  Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.

Authors:  Samuel J Klempner; Steven B Maron; Leah Chase; Samantha Lomnicki; Zev A Wainberg; Daniel V T Catenacci
Journal:  Oncologist       Date:  2018-11-23

5.  PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Authors:  Takahiro Kamada; Yosuke Togashi; Christopher Tay; Danbee Ha; Akinori Sasaki; Yoshiaki Nakamura; Eiichi Sato; Shota Fukuoka; Yasuko Tada; Atsushi Tanaka; Hiromasa Morikawa; Akihito Kawazoe; Takahiro Kinoshita; Kohei Shitara; Shimon Sakaguchi; Hiroyoshi Nishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-26       Impact factor: 11.205
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.